incagn01876
mAbexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02697591)
Timeline
Indications
Mechanism of action
TNFRSF18 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- incagn01876
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05359692 | Phase 2 | Jan 13, 2023 | Incyte |
| NCT04470024 | Phase 1 | Sep 1, 2020 | Providence Health & Services |
| NCT04225039 | Phase 2 | Jan 31, 2020 | Incyte, University of Pennsylvania |
| NCT03277352 | Phase 1/Phase 2 (Phase 2) | Nov 21, 2017 | Incyte |
| NCT03126110 | Phase 1/Phase 2 (Phase 2) | Apr 13, 2017 | Incyte |
| NCT02697591 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Incyte |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 5 | 4 | 1 | 2016 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1